Key Takeaways
- Oncology Repricing: Moderna stock jumped 7% on Thursday, September 24, closing at $195 as investors kept betting on intismeran autogene’s Phase 3 melanoma data due at ESMO on October 24.
- Street Split: The 23 analysts covering Moderna stock are split 4 buys, 1 outperform, 16 holds, 1 underperform, and 1 sell, with a mean target of $120 that sits 39% below Thursday’s close.
- Ceiling Breach: Wall Street’s highest target, $170, sits 13% below Moderna stock’s Thursday close.
- Platform Pivot: CEO Stéphane Bancel told the Bernstein Healthcare Conference on September 23 that Moderna has never been a COVID-19 vaccine company, reframing it as an mRNA platform builder with oncology at the center.
Access Moderna stock’s full analyst history and price target trends on TIKR for free →
Why Moderna Stock Jumped 7% on Thursday’s Oncology Bet
Moderna stock (MRNA) climbed 7% on Thursday, September 24, closing at $195 as traders extended a rally built on the growing conviction that intismeran autogene will clear its biggest test next month. The personalized cancer vaccine, developed with Merck, already hit its primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival in patients with resected melanoma when tested alongside Keytruda. Moderna has not shown the underlying survival curves yet. That is the point.
Wall Street reacted fast when the initial data broke in August. TD Cowen analyst Tyler Van Buren, addressing the trial’s readout at the time, called it a landmark moment and significant validation of Moderna’s underlying mRNA platform. William Blair’s Myles Minter went further, upgrading the stock and projecting the melanoma indication alone could eventually generate $5.4 billion in peak annual sales. Those calls set the floor under the stock heading into September.
The company disclosed on September 21 that three abstracts on the therapy were accepted for the European Society for Medical Oncology Congress in Madrid, with the melanoma data landing a Presidential Symposium slot on October 24, the session ESMO reserves for first-time disclosures of practice-changing trials. Earlier-stage data on pancreatic cancer and early-stage lung cancer are also slated for poster sessions, extending the drug’s reach beyond melanoma alone. Investors have spent the days since bidding up the stock on the assumption that a slot that prestigious does not go to data that disappoints.
None of this changes what actually gets disclosed on October 24. The market has priced Moderna stock for a positive outcome well before seeing the hazard ratios that will decide it.
Bancel’s Bernstein Remarks Add a Second Layer to Moderna Stock
Thursday’s move did not run on oncology alone. At the Bernstein Healthcare Conference on September 23, CEO Stéphane Bancel told the room: “Moderna has never been a COVID-19 vaccine company. Moderna has been, since day one, an mRNA platform company.” He pointed to three standing franchises now, vaccines, oncology, and rare diseases such as propionic acidemia, and framed COVID as an emergency response the company never planned to build its identity around.
That framing landed a day before Moderna stock’s biggest single-session gain in weeks, and it gave momentum traders a story bigger than one melanoma readout to buy into. Chief Development Officer David Berman added technical color on the mechanism, telling the same audience that Moderna’s intratumoral approach does not need a PD-1 pathway to be active, a detail aimed at investors trying to gauge how far the platform extends past this one trial.
Put Moderna stock’s ESMO catalyst and platform pivot side by side on TIKR for free →
Moderna Stock’s Rally Has Outrun Every Street Target
The 23 analysts covering Moderna stock carry a split of 4 buys, 1 outperform, 16 holds, 1 underperform, and 1 sell, and their mean target of $120 sits 39% below Thursday’s $195 close. Even the single highest target on the sheet, $170, trails the stock by 13%. The median comes in at $125, closer to the mean than the high end, which means the bullish outlier is not doing much to pull the average toward where shares actually trade.
That gap is new. Back in June 2025, when Moderna stock traded near $28, the mean target of $48 sat 72% above the price, and analysts stayed roughly that far ahead through September of that year. The relationship flipped by March 2026, when the mean target first slipped behind the stock, and the shortfall has widened almost every quarter since: 14% behind in March, 35% behind in June, and 39% behind now.
Coverage has thinned too, from 22 analysts issuing price targets in mid-2025 to 18 today. But the ratings mix just swung bullish. Buys doubled from 2 to 4 in a single quarter, and underperforms fell from 3 to 1, even as the dollar targets stayed pinned well under the tape. Analysts are warming to the direction of the story faster than they are willing to chase the price with new numbers.
See how far Moderna stock has run past its mean target on TIKR for free →
Should You Invest in Moderna, Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Moderna, Inc. stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Moderna, Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze MRNA stock on TIKR for Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
